India's Supreme Court has set an important precedent in refusing to grant a patent to Novartis for an updated version of its cancer drug Glivec. The verdict will allow generic drug makers within the country to continue selling cheap versions of the drug, which is used to treat chronic myeloid leukemia and other cancers. The BBC notes that Novartis' drug costs $2,600, while generic versions of the drug cost just $175. The court's decision is based on one specific part of India's patent law: secti...
India's Supreme Court has set an important precedent in refusing to grant a patent to Novartis for an updated version of its cancer drug Glivec. The verdict will allow generic drug makers within the country to continue selling cheap versions of the drug, which is used to treat chronic myeloid leukemia and other cancers. The BBC notes that Novartis' drug costs $2,600, while generic versions of the drug cost just $175. The court's decision is based on one specific part of India's patent law: secti...
Share this Article
Comment on this Article
Recommended
Please to comment